Position in EXEL
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$362,588
+$106,878 QoQ
Shares Held
6,664
+11.8% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#489
of 751 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Sagewood Asset Management LP holds $3,255,470 across 8 Biotechnology names. EXEL ranks #5 (11.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
5,420 | $614,411 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
892 | $556,197 | |
| 3 | RPRX |
Royalty Pharma plc
|
8,972 | $503,060 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
809 | $401,854 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
6,664 | $362,588 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
5,750 | $329,015 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
3,175 | $248,507 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
6,777 | $239,838 |
All Filings in EXEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $362,588 | 6,664 | Shares | Sole | 2026-07-29 | |
| 2026-03-31 | $255,710 | 5,962 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||